JP6209516B2 - 癌治療に使用するための化合物 - Google Patents

癌治療に使用するための化合物 Download PDF

Info

Publication number
JP6209516B2
JP6209516B2 JP2014525551A JP2014525551A JP6209516B2 JP 6209516 B2 JP6209516 B2 JP 6209516B2 JP 2014525551 A JP2014525551 A JP 2014525551A JP 2014525551 A JP2014525551 A JP 2014525551A JP 6209516 B2 JP6209516 B2 JP 6209516B2
Authority
JP
Japan
Prior art keywords
cancer
tumor
compound
group
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014525551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505530A (ja
JP2015505530A5 (enExample
Inventor
アール． コナー，ジェイムス
アール． コナー，ジェイムス
イ，サンヨン
ジェイムス ブラウン，トーマス
ジェイムス ブラウン，トーマス
マーティン コウレイ，フィリップ
マーティン コウレイ，フィリップ
Original Assignee
ニューホープ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューホープ，エルエルシー filed Critical ニューホープ，エルエルシー
Publication of JP2015505530A publication Critical patent/JP2015505530A/ja
Publication of JP2015505530A5 publication Critical patent/JP2015505530A5/ja
Application granted granted Critical
Publication of JP6209516B2 publication Critical patent/JP6209516B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014525551A 2011-08-18 2012-08-15 癌治療に使用するための化合物 Expired - Fee Related JP6209516B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524826P 2011-08-18 2011-08-18
PCT/IB2012/054160 WO2013024447A1 (en) 2011-08-18 2012-08-15 Compounds for use in cancer therapy

Publications (3)

Publication Number Publication Date
JP2015505530A JP2015505530A (ja) 2015-02-23
JP2015505530A5 JP2015505530A5 (enExample) 2015-09-17
JP6209516B2 true JP6209516B2 (ja) 2017-10-04

Family

ID=47010660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014525551A Expired - Fee Related JP6209516B2 (ja) 2011-08-18 2012-08-15 癌治療に使用するための化合物

Country Status (4)

Country Link
US (2) US9878998B2 (enExample)
EP (1) EP2744500A1 (enExample)
JP (1) JP6209516B2 (enExample)
WO (1) WO2013024447A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6209516B2 (ja) 2011-08-18 2017-10-04 ニューホープ，エルエルシー 癌治療に使用するための化合物
CN103405437B (zh) * 2013-08-30 2015-01-21 苏州大学 一种pi3k小分子抑制剂及其应用
GB201805386D0 (en) * 2018-03-31 2018-05-16 Opal Oncology Ltd Pharmaeutical compounds
RU2717246C1 (ru) * 2019-06-17 2020-03-19 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ПГФА) Этил 4-(5-бензоил-6-(4-(диэтиламино)фенил)-4-гидрокси-2-тиоксогексагидропиримидин-4-карбоксамино)бензоат, проявляющий анальгетическое и противовоспалительное действие
WO2021035176A1 (en) * 2019-08-21 2021-02-25 Regents Of The University Of Minnesota Pigmented and fluorescent compounds derived from the addition of a primary or secondary amine to an aldehyde
CN113292448B (zh) * 2021-06-25 2022-06-28 中山大学 一种茚酮类亚胺衍生物及其制备方法与应用
CN117777030B (zh) * 2023-12-22 2026-04-21 郑州大学 一种粘度响应型发光探针、制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012080A1 (en) 1988-06-08 1989-12-14 Eastman Kodak Company Novel merocyanine dyes
GB0013655D0 (en) * 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
AU2003225668A1 (en) * 2002-03-01 2003-09-16 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
EP1682115A4 (en) * 2003-11-07 2010-07-28 Univ Emory HIF-1 HEMMER AND APPLICATION METHOD THEREFOR
US20100055116A1 (en) 2006-04-13 2010-03-04 Liou Hsiou-Chi Methods and Compositions for Targeting c-Rel
WO2009018219A2 (en) 2007-07-28 2009-02-05 University Of Chicago Methods and compositions for modulating rad51 and homologous recombination
EP2222326B2 (en) 2007-11-21 2015-02-25 Vib Vzw Inhibitors of malt1 proteolytic activity and uses thereof
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8304421B2 (en) * 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
US20130035304A1 (en) 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
JP6209516B2 (ja) 2011-08-18 2017-10-04 ニューホープ，エルエルシー 癌治療に使用するための化合物

Also Published As

Publication number Publication date
US20180134691A1 (en) 2018-05-17
WO2013024447A1 (en) 2013-02-21
EP2744500A1 (en) 2014-06-25
US20150065531A1 (en) 2015-03-05
US9878998B2 (en) 2018-01-30
US9994554B2 (en) 2018-06-12
JP2015505530A (ja) 2015-02-23

Similar Documents

Publication Publication Date Title
US9994554B2 (en) Barbiturate and thiobarbiturate compounds for use in cancer therapy
CN113164495B (zh) E3连接酶的共价靶向
US10590109B2 (en) Heterocyclic compounds used as FGFR inhibitors
US9273052B2 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
JP6912486B2 (ja) Ｒｓｋ阻害剤として有用なカルボキサミド誘導体
RU2521394C2 (ru) Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток
JP5188988B2 (ja) ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法
JP5102839B2 (ja) 有糸分裂進行を阻害するための化合物
US20050245508A1 (en) Treatment of malignant gliomas with TGF-beta inhibitors
JP2023512040A (ja) 化合物及びその使用
CN115996716A (zh) Eif4a抑制剂组合
ES2726717T3 (es) Imidazopiridinas sustituidas con isoxazolilo
JP2010510312A (ja) 放射線増感剤を用いた放射線感受性腫瘍に対する方法
JP2021519786A (ja) チエノピリミジノン化合物
CN118159534A (zh) 抑制PI3K同工型α的化合物和用于治疗癌症的方法
US9724331B2 (en) Use of maleimide derivatives for preventing and treating leukemia
CN113811324A (zh) 小分子局部黏着斑激酶(fak)抑制剂
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
TWI290046B (en) Phenanthroindolizidine alkaloids
US20240197729A1 (en) ALK-5 Inhibitors and Uses Thereof
US12570668B2 (en) Single molecule compounds providing multi-target inhibition of BTK and other proteins and methods of use thereof
Kamble et al. Synthesis of new 4-chloro-(5-aliphatic/cyclic saturated amino)-2-o-chlorophenyl-(2H)-pyridazin-3-one derivatives as anticancer, antiangiogenic, and antioxidant agents
WO2014106763A1 (en) Pyridopyrazines as anticancer agents
CN122055154A (zh) 组合疗法
CN117355304A (zh) Alk-5抑制剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170911

R150 Certificate of patent or registration of utility model

Ref document number: 6209516

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees